肿瘤热休克蛋白70联合IL-2对荷瘤小鼠的治疗作用

The therapeutic efficacy of tumor-derived heat shock protein70 combining interleu-kin-2 on tumor-bearing mice

目的:研究肿瘤热休克蛋白70(HSP70)与IL-2联合应用对荷瘤小鼠的治疗作用。方法:用液相色谱法纯化小鼠肿瘤细胞 株中的HSP70。对纯化产物用SDS-PAGE及Western blot进行定性分析,再用毛细管电泳鉴定其纯度。通过动物实验,观察HSP70与IL-2单独应用及联合应用的抗肿瘤作用。结果:HSP70与IL-2联合应用较单独应用的治疗效果更明显,但治疗作用仍以HSP70为主。单独应用IL-2只能延长小鼠的生存期限[平均为(36.6±13.0)d],而HSP70 10μg组可使40％荷瘤小鼠的肿瘤最终全部消退,生存期最长者>90[平均生存期(>59.2±29.6)d],与对照组相比较差异显著(P<0.01)。HSP70与IL-2联合应用组可使60％荷瘤小鼠的肿瘤完全消退,平均生存期(>70.8±26.5)d,与对照组相比差异十分显著(P<0.01)。结论:合适剂量的HSP70与IL-2联合应用,对荷瘤小鼠有明显的治疗作用,可明显抑制肿瘤进展,提高生存率。以上结果对研究人类恶性肿瘤的免疫治疗具有较大的参考价值。

AIM: To investigate the therapeutic efficacy of the combination of tumor-derived HSP70 and IL-2 on tumor-bearing mice. METHODS: HSP70 was purified from the murine tumor cell line by liquid chromatography. And then identified by SDS-PAGE and Western blot; the purity of purified product was analyzed by capillary electrophoresis. The anti-tumor efficacies of mono-administration of HSP70 or IL-2 and their combination were observed by zoopery. RESULTS: Combination of HSP70 and IL-2 was more effective than either of the two therapeutic agents alone in treating tumor-bearing mice. 10 ug HSP70 displayed obviously therapeutic effect no matter applied alone or combined with IL-2. The averaged life span of the mice treated with IL-2 was only 36. 6 ± 13. 0 days, while 40% of the mice treated with 10 ug HSP70, tumors disappeared eventually and their survival time was more than 90 days, and the averaged life span of this group was over 59. 2 ± 29.6 days. HSP70 plus IL-2 could get tumors disappeared completely in 60% of mice, averaged life time of this group was over 70. 8 ±26.5 days. CONCLUSION: The Combination of HSP70 and IL-2 demonstrated apparently therapeutic effect on tumor-bearing mice. The results will be of greater value to the study on the immunotherapy of human malignant tumors.